@celestevmoss.bsky.socialAt @johngreensbluesky.bsky.social’s book tour stop in Tulsa the other night, tons of people stopped by the @tbfighters.org table to write a postcard about why access to affordable HIV prevention matters to them. Here’s a selection of what they had to say! #2shots$40everywhere #lenacapavir
@avac.orgFollow the rollout of injectable #lenacapavir (LEN) for #HIV #PrEP with AVAC’s latest resources, including:
1️⃣ Our online tracker sharing steps, timelines & stakeholders responsible for moving each step fwd, www.prepwatch.org/tracking-len...
2️⃣ LEN regulatory status, avac.org/resource/inf...
@avac.orgAnother important read by @bhekisisa.org, bhekisisa.org/opinion/2026....
"South Africa helped prove that #LEN works. The next question is whether we can make it affordable and widely available, while also strengthening our ability to make medicines in Africa."
@ensonhbr.bsky.socialHIV prevention drug hailed as breakthrough, but who gets access?
Lenacapavir, a twice-a-year injection could transform HIV prevention, but it will not be available to all.
#Lenacapavir #Türkiye #SonDakika #Gündem #AlJazeera
Daha fazlası: https://t.me/ensonhbr
@globalvisibility.bsky.social
@hanc-legacyproject.bsky.social🔬 What does it take to move a scientific breakthrough from the laboratory to real-world impact?
Explore the scientific journey of lenacapavir: from early discovery to its impact on HIV prevention and treatment. 💥
💻 REGISTER: tinyurl.com/LENimpact
@ghtcoalition.orgLast week, Gilead announced that it has expanded its voluntary licensing agreements with partners, who are already manufacturing the recently approved twice-yearly #lenacapavir for #HIV prevention, to include investigational once-yearly lenacapavir.
@deutscheaidshilfe.bsky.socialIn Studien wird derzeit die medikamentöse #HIV- Prophylaxe #PrEP mit dem nur 1 x jährlich per Spritze verabreichten Wirkstoff #Lenacapavir erprobt. Der Hersteller Gilead hat seine Lizenzvereinbarung mit 6 Generikaherstellern für 120 Länder mit niedrigen Einkommen um diese Option ergänzt.
@deutscheaidshilfe.bsky.social2️⃣ Zugangsmöglichkeit zur #HIV- #PrEP mit dem langwirksamen Wirkstoff #Lenacapavir: Gilead und die Panamerikanische Gesundheitsorganisation PAHO sollen transparent über Preise, Liefermengen und Zeitleisten berichten, fordern NGOs. Dies sei unerlässlich für die Planung und breite Anwendung.
@deutscheaidshilfe.bsky.social🧵1️⃣ Nach der Ankündigung einer Vereinbarung von Gilead und der Panamerikanischen Gesundheitsorganisation PAHO über den möglichen Zugang zur #HIV- Prophylaxe mit dem langwirksamen Medikament #Lenacapavir fordern Aktivist*innen, aus der Zugangsmöglichkeit echten Zugang zu machen.
/2
free drug #healthcare #free #medicine #lenacapavir
@avac.orgThis week's #GlobalHealthWatch covers new pathways for #lenacapavir access, push back on the proposed #NIAID reorganization, new Global Fund data, which shows #HIV prevention is taking a hit & scientists file a class action lawsuit challenge NIH grant screening.
@healthlawadamh.bsky.social#MSF: "Pharma monopoly limits impact of new PAHO deal for #HIV prevention drug - Efforts to create a regional pathway for #lenacapavir are welcome, but Gilead’s continued control over pricing and supply means that the drug will remain out of reach for most in Latin America and the Caribbean."
@oliveryun.bsky.socialGilead announced a “pathway” for access to HIV prevention drug #lenacapavir in Latin American countries excluded from their generics deal - but critical details like price and supply are unknown:
www.doctorswithoutborders.org/latest/pharm...
@cranberrymuffin.bsky.socialHey, @gilead.com you don't have to hire a new PR team! You can just sell #Lenacapavir for #2Shots$40Everywhere. But if anybody wanted to apply and tell Gilead exactly how they might improve their brand image, I think it could be a great idea.
@celestevmoss.bsky.social#2Shots$40Everywhere #lenacapavir #peopleoverprofits #tbfighter @tbfighters.org
@bhekisisa.org💉 Want #LEN but not sure what actually happens at the clinic?
HIV test ✔️
2 pills ✔️2 tummy or buttocks jabs ✔️
2 more pills the next day ✔️
Back in 6 months ✔️
We went to a clinic to make you a step-by-step LEN cheat sheet.
@deutscheaidshilfe.bsky.social2️⃣ Durch eine Vereinbarung von Gilead mit der Pan American Helath Organization sollen auc Argentinien, Brasilien, Chile, Costa Rica, Ecuador, El Salvador, Guatemala, Kolumbien, Mexico, Panama, Paraguay, Peru, Uruguay und Venezuela Zugang zur #Lenacapavir- #PrEP zum Schutz vor #HIV bekommen.
@deutscheaidshilfe.bsky.socialDer Pharmakonzern Gilead und die Pan American Health Organization (PAHO) haben eine Vereinbarung über die Beschleunigung des Zugangs zur medikamentösen #HIV- #PrEP mit dem langwirksamen #Lenacapavir bekanntgegeben. Zugang sollen so auch Länder mit mittleren Einkommen bekommen.
/2
@healthlawadamh.bsky.social👀UK's National Institute for Health and Care Excellence (NICE) recommends AGAINST #Lenacapavir as pre-exposure prophylaxis (PrEP) for HIV.
As they note, this is draft guidance, currently out for consultation, so recommendations could change...
www.nice.org.uk/guidance/gid...
![Screenshot reading "CONFIDENTIAL UNTIL PUBLISHED
Draft guidance consultation – Lenacapavir for preventing HIV-1 in adults and young people [ID6495]
Issue date: September 2026
© NICE 2026. All rights reserved. Subject to Notice of rights. Page 3 of 28
1 Recommendations
1.1 Lenacapavir should not be used as pre-exposure prophylaxis (PrEP)
alongside safer sex practices to reduce the risk of sexually acquired HIV-1
infection in adults and young people at high risk of getting HIV-1 and who
weigh at least 35 kg.
1.2 This recommendation is not intended to affect preventive treatment with
lenacapavir that was started in the NHS before this guidance was
published. People having lenacapavir outside this recommendation may
continue without change to the funding arrangements in place for them
before this guidance was published, until they and their NHS healthcare
professional consider it appropriate to stop.
What this means in practice
These are NICE’s draft recommendations. If these recommendations become
final, lenacapavir would not be required to be funded and should not be used
routinely in the NHS in England for the condition and population in the
recommendations.
This is because the available evidence does not suggest that lenacapavir is value
for money in this population."](https://cdn.bsky.app/img/feed_fullsize/plain/did:plc:ojq7ut3gnsgnu3pwdv6rh3wc/bafkreiehdgmi734rqapxyxkfocdst64tpfrajuojipp2ui6qsvkhui4y6y@jpeg)